From England 1998: Montelukast
Montelukast (Singulair) is a ...

From England 1998: Montelukast
Montelukast (Singulair) is a leukotriene antagonist for use as an add-on therapy in patients with mild to moderate asthma who are inadequately controlled by inhaled corticosteroids and short acting beta2-agonists. Since it was marketed in January 1998, CSM Mersey has received 31 yellow cards detailing 47 suspected reactions to montelukast including: • 15 (32%) CNS disorders including headache and drowsiness • 14 (30%) GI disorders including abdominal pain and indigestion • 5 (11%) skin disorders including sweating • 7 (15%) musculoskeletal disorders including arthralgia and cramps • 2 (4%) psychiatric disorders. 26 of these reactions were not listed in the Summary of Product Characteristics at the time of reporting. http://www.liv.ac.uk/~druginfo/csm/ADR_bulletin14.pdf